Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Alessia Cimadamore, M.D.

Title
Institution
Department
Address
Phone

Biography
Università Politecnica delle Marche, AnconaMD07/2014Medicine
Bologna University, Bologna11/2019Pathology
2019 - 2020
ISUP Stipend Award

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Krajewski W, Aumatell J, Subiela JD, Nowak L, Tukiendorf A, Moschini M, Basile G, Poletajew S, Malkiewicz B, Giudice FD, Maggi M, Chung BI, Cimadamore A, Galosi AB, Fave RFD, D'Andrea D, Shariat SF, Hornak J, Babjuk M, Chorbinska J, Teoh JY, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Panunzio A, Alvarez-Maestro M, Simone G, Mastroianni R, Laszkiewicz J, Lonati C, Zamboni S, Simeone C, Niedziela L, Candela L, Macek P, Contieri R, Hidalgo BG, Rivas JG, Sosnowski R, Mori K, Mir C, Soria F, González-Padilla DA, Faba ÒR, Palou J, Ploussard G, Rajwa P, Halon A, Laukhtina E, Pradere B, Tully K, Burgos FJ, Cidre MÁJ, Szydelko T. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. Urol Oncol. 2022 Jul 15. PMID: 35851185.
    Citations:    Fields:    
  2. Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. J Pers Med. 2022 Jun 29; 12(7). PMID: 35887569; PMCID: PMC9321150.
    Citations:    
  3. Cimadamore A, Teoh JY, DI Trapani E, Krajewski W, Tan WS, Mori K, Del Giudice F, Carrion DM, Moschini M. A gender-related dichotomy in bladder cancer. Minerva Urol Nephrol. 2022 06; 74(3):376-378. PMID: 35607787.
    Citations:    Fields:    Translation:Humans
  4. Santoni M, Massari F, Rizzo A, Mollica V, Cimadamore A, Montironi R, Battelli N. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori. 2022 May 20; 3008916221090323. PMID: 35593453.
    Citations:    Fields:    
  5. Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 Sep 01; 40(25):2913-2923. PMID: 35442713; PMCID: PMC9426835.
    Citations: 3     Fields:    
  6. Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, Cimadamore A, Abufaraj M, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupret M, Babjuk M, Witjes JA, Shariat SF, Pradere B. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. Eur Urol Focus. 2022 Mar 22. PMID: 35337773.
    Citations:    Fields:    
  7. Lorenzoni M, De Felice D, Beccaceci G, Di Donato G, Foletto V, Genovesi S, Bertossi A, Cambuli F, Lorenzin F, Savino A, Avalle L, Cimadamore A, Montironi R, Weber V, Carbone FG, Barbareschi M, Demichelis F, Romanel A, Poli V, Del Sal G, Julio MK, Gaspari M, Alaimo A, Lunardi A. ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3ß dependent Nkx3.1 degradation. Cancer Lett. 2022 05 28; 534:215612. PMID: 35259458; PMCID: PMC8968219.
    Citations:    Fields:    Translation:Animals
  8. Stangl-Kremser J, Muto G, Grosso AA, Briganti A, Comperat E, Di Maida F, Montironi R, Remzi M, Pradere B, Soria F, Albisinni S, Roupret M, Shariat SF, Minervini A, Teoh JY, Moschini M, Cimadamore A, Mari A. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. Urol Oncol. 2022 06; 40(6):243-261. PMID: 35241364.
    Citations: 1     Fields:    Translation:Humans
  9. Cimadamore A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, D'Andrea D, Shariat SF, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, Moschini M. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? Urol Oncol. 2022 06; 40(6):273.e11-273.e20. PMID: 35216892.
    Citations:    Fields:    Translation:Humans
  10. Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022 02 15; 28(4):748-755. PMID: 34921022; PMCID: PMC8866215.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  11. Al-Obaidy KI, Saleeb RM, Trpkov K, Williamson SR, Sangoi AR, Nassiri M, Hes O, Montironi R, Cimadamore A, Acosta AM, Alruwaii ZI, Alkashash A, Hassan O, Gupta N, Osunkoya AO, Sen JD, Baldrige LA, Sakr WA, Idrees MT, Eble JN, Grignon DJ, Cheng L. Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. Mod Pathol. 2022 Sep; 35(9):1279-1286. PMID: 35152262.
    Citations:    Fields:    
  12. Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, Cimadamore A, Farolfi A, Montironi R, Fanti S, Massari F. PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming? Cancers (Basel). 2022 Feb 11; 14(4). PMID: 35205654; PMCID: PMC8869833.
    Citations: 1     
  13. Lopez-Beltran A, Blanca A, Cimadamore A, Montironi R, Luque RJ, Volavšek M, Cheng L. T1 bladder carcinoma with variant histology: pathological features and clinical significance. Virchows Arch. 2022 May; 480(5):989-998. PMID: 35122124; PMCID: PMC9033727.
    Citations:    Fields:    Translation:Humans
  14. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B. Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42]. Eur Urol Oncol. 2022 Aug; 5(4):480-481. PMID: 35063436.
    Citations:    Fields:    
  15. Mollica V, Marchetti A, Rosellini M, Nuvola G, Rizzo A, Santoni M, Cimadamore A, Montironi R, Massari F. An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. Int J Mol Sci. 2021 Dec 16; 22(24). PMID: 34948314.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  16. Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles. Pathol Res Pract. 2022 Jan; 229:153737. PMID: 34952428.
    Citations:    Fields:    Translation:Humans
  17. Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. Artificial intelligence and prostate cancer: Advances and challenges. Urologia. 2022 Aug; 89(3):388-390. PMID: 34877911.
    Citations:    Fields:    Translation:Humans
  18. Morelli MB, Amantini C, Rossi de Vermandois JA, Gubbiotti M, Giannantoni A, Mearini E, Maggi F, Nabissi M, Marinelli O, Santoni M, Cimadamore A, Montironi R, Santoni G. Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. Cancers (Basel). 2021 Nov 28; 13(23). PMID: 34885101.
    Citations: 2     
  19. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021 12; 4(6):927-942. PMID: 34753702.
    Citations: 4     Fields:    Translation:Humans
  20. Lopez-Beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L. Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. Cancers (Basel). 2021 Nov 01; 13(21). PMID: 34771663.
    Citations:    
  21. Aurilio G, Santoni M, Massari F, Cimadamore A, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers (Basel). 2021 Oct 18; 13(20). PMID: 34680377.
    Citations: 1     
  22. Montironi R, Lopez-Beltran A, Cimadamore A, Cheng L, Scarpelli M. What's the future in uropathology. Urologia. 2021 Nov; 88(4):265-266. PMID: 34612741.
    Citations:    Fields:    Translation:Humans
  23. Murrone A, Cantini L, Pecci F, Cognigni V, Copparoni C, Rinaldi S, Fiordoliva I, Monaco F, Rubini C, Barbisan F, Cimadamore A, Giampieri R, Bianchi F, Tomasetti M, Amati M, Santarelli L, Berardi R. BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. J Thorac Dis. 2021 Oct; 13(10):5741-5751. PMID: 34795923; PMCID: PMC8575852.
    Citations: 1     
  24. Rocco B, Cimadamore A, Sighinolfi MC, Assumma S, Montironi R. Reply to Eoin Dinneen, Jon Oxley, and Greg Shaw's Letter to the Editor re: Bernardo Rocco, Luca Sarchi, Simone Assumma, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.021. Eur Urol. 2021 11; 80(5):e122-e123. PMID: 34483006.
    Citations:    Fields:    Translation:Humans
  25. Montironi R, Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M. The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. Arch Pathol Lab Med. 2021 09 01; 145(9):1049-1050. PMID: 34170299.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  26. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope. Minerva Urol Nephrol. 2022 02; 74(1):127-129. PMID: 34263745.
    Citations:    Fields:    Translation:Humans
  27. Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Massari F, Santoni M, Scarpelli M, Cheng L, Montironi R. Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers (Basel). 2021 Jul 11; 13(14). PMID: 34298683.
    Citations: 1     
  28. Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate. Eur Urol. 2021 09; 80(3):e81-e82. PMID: 34148712.
    Citations:    Fields:    Translation:Humans
  29. Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Bründl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91: Image Analysis, Nuclear Abnormality Index, and Pattern Recognition Analysis. Eur Urol Oncol. 2021 08; 4(4):671-673. PMID: 34144939.
    Citations:    Fields:    Translation:Humans
  30. Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci. 2021 Jun 09; 22(12). PMID: 34207825; PMCID: PMC8226484.
    Citations:    Fields:    Translation:Humans
  31. Albisinni S, Moschini M, Di Trapani E, Soria F, Mari A, Aziz A, Teoh J, Laukhtina E, Mori K, D'Andrea D, Carrion DM, Krajewski W, Abufaraj M, Cimadamore A, Tan WS, Flippot R, Khalifa J, Gonsette K, Pradere B. Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers. World J Urol. 2022 Jun; 40(6):1317-1323. PMID: 34076754.
    Citations: 2     Fields:    Translation:Humans
  32. Montironi R, Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M. Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment. Virchows Arch. 2021 07; 479(1):227-229. PMID: 34032916.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  33. Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. Int J Mol Sci. 2021 May 24; 22(11). PMID: 34073818.
    Citations: 3     Fields:    Translation:HumansCells
  34. Santoni M, Tombesi F, Cimadamore A, Montironi R, Piva F. Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments. Front Oncol. 2021; 11:634818. PMID: 34046340.
    Citations:    
  35. Montironi R, Scarpelli M, Cimadamore A, Mikuz G. Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations. Eur Urol Focus. 2022 May; 8(3):882-884. PMID: 33994166.
    Citations:    Fields:    
  36. Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping. Pathobiology. 2021; 88(5):323-326. PMID: 33975322.
    Citations:    Fields:    Translation:Humans
  37. Rocco B, Sarchi L, Assumma S, Cimadamore A, Montironi R, Reggiani Bonetti L, Turri F, De Carne C, Puliatti S, Maiorana A, Pellacani G, Micali S, Bianchi G, Sighinolfi MC. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. 2021 Dec; 80(6):724-729. PMID: 33965288.
    Citations:    Fields:    Translation:Humans
  38. Belenchia M, Rocchetti G, Maestri S, Cimadamore A, Montironi R, Santoni M, Merelli E. Agent-Based Learning Model for the Obesity Paradox in RCC. Front Bioeng Biotechnol. 2021; 9:642760. PMID: 33996779.
    Citations: 1     
  39. Lopez-Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Hum Pathol. 2021 Jul; 113:67-83. PMID: 33887300.
    Citations: 3     Fields:    Translation:Humans
  40. Cimadamore A, Lopez-Beltran A, Scarpelli M, Montironi R. Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91. Eur Urol. 2021 06; 79(6):e172-e173. PMID: 33838958.
    Citations:    Fields:    Translation:Humans
  41. Galosi AB, Palagonia E, Scarcella S, Cimadamore A, Lacetera V, Delle Fave RF, Antezza A, Dell'Atti L. Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology. Arch Ital Urol Androl. 2021 Mar 22; 93(1):92-100. PMID: 33754619.
    Citations: 3     Fields:    Translation:Humans
  42. Cimadamore A, Lopez-Beltran A, Scarpelli M, Montironi R. RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, https://doi.org/10.1016/j.urolonc.2020.12.007 (Low grade papillary intra-urothelial neoplasia). Urol Oncol. 2021 05; 39(5):308-309. PMID: 33674150.
    Citations:    Fields:    Translation:Humans
  43. Aurilio G, Cimadamore A, Lopez-Beltran A, Scarpelli M, Massari F, Verri E, Cheng L, Santoni M, Montironi R. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. Transl Androl Urol. 2021 Mar; 10(3):1521-1529. PMID: 33850786.
    Citations: 4     
  44. Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl Androl Urol. 2021 Mar; 10(3):1506-1520. PMID: 33850785; PMCID: PMC8039604.
    Citations: 7     
  45. Montironi R, Cheng L, Cimadamore A, Mazzucchelli R, Scarpelli M, Santoni M, Massari F, Lopez-Beltran A. Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups? Transl Androl Urol. 2021 Mar; 10(3):1530-1540. PMID: 33850787.
    Citations: 2     
  46. Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Montironi R. Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now. Transl Androl Urol. 2021 Mar; 10(3):1499-1505. PMID: 33850784.
    Citations: 2     
  47. Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R. Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Transl Androl Urol. 2021 Mar; 10(3):1562-1568. PMID: 33850790.
    Citations: 2     
  48. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Schiavina R, Cheng L, Lopez-Beltran A, Brunocilla E, Montironi R, Massari F. TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. Transl Androl Urol. 2021 Mar; 10(3):1541-1552. PMID: 33850788.
    Citations: 3     
  49. Rocco B, Cimadamore A, Sarchi L, Bonetti LR, Bertoni L, Azzoni P, Assumma S, Turri F, Bozzini G, Eissa A, Micali S, Bianchi G, Maiorana A, Montironi R, Pellacani G, Sighinolfi MC. Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: a narrative review. Transl Androl Urol. 2021 Mar; 10(3):1569-1580. PMID: 33850791.
    Citations: 2     
  50. Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Transl Androl Urol. 2021 Mar; 10(3):1581-1587. PMID: 33850792.
    Citations: 2     
  51. Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, Battelli N. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opin Investig Drugs. 2021 Mar; 30(3):245-251. PMID: 33599169.
    Citations: 5     Fields:    Translation:HumansAnimals
  52. Montironi R, Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Mikuz G. Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. Pathol Res Pract. 2021 Mar; 219:153377. PMID: 33631479.
    Citations:    Fields:    Translation:Humans
  53. Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021 Feb 04; 22(4). PMID: 33557050.
    Citations: 5     Fields:    Translation:HumansAnimals
  54. Santoni M, Massari F, Santoni G, Cimadamore A, Montironi R, Battelli N. Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Eur Urol. 2021 06; 79(6):887-889. PMID: 33549360.
    Citations:    Fields:    Translation:HumansCells
  55. Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, Cimadamore A, Scarpelli M, Bonucci C, Andrini E, Errani C, Santoni M, Montironi R, Massari F. Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers (Basel). 2021 Feb 01; 13(3). PMID: 33535541.
    Citations: 11     
  56. Giulietti M, Cecati M, Sabanovic B, Scirè A, Cimadamore A, Santoni M, Montironi R, Piva F. The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors. Diagnostics (Basel). 2021 Jan 30; 11(2). PMID: 33573278.
    Citations: 3     
  57. Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Cartenì G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics (Basel). 2021 Jan 18; 11(1). PMID: 33477676.
    Citations:    
  58. Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021 Jan 03; 13(1). PMID: 33401585.
    Citations: 37     
  59. Cheng L, Mann SA, Lopez-Beltran A, Chovanec M, Santoni M, Wang M, Albany C, Adra N, Davidson DD, Cimadamore A, Montironi R, Zhang S. Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. Methods Mol Biol. 2021; 2195:31-47. PMID: 32852755.
    Citations:    Fields:    Translation:Humans
  60. Gevaert T, Cimadamore A, Montironi R, Eckstein M. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. Curr Drug Targets. 2021; 22(2):162-170. PMID: 32386490.
    Citations: 5     Fields:    Translation:Humans
  61. Montironi R, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M. Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy. Cells. 2020 12 24; 10(1). PMID: 33374303.
    Citations: 1     Fields:    Translation:Humans
  62. Santoni M, Piva F, Cimadamore A, Giulietti M, Battelli N, Montironi R, Cosmai L, Porta C. Exploring the Spectrum of Kidney Ciliopathies. Diagnostics (Basel). 2020 Dec 16; 10(12). PMID: 33339422.
    Citations: 1     
  63. Piva F, Tartari F, Giulietti M, Aiello MM, Cheng L, Lopez-Beltran A, Mazzucchelli R, Cimadamore A, Cerqueti R, Battelli N, Montironi R, Santoni M. Predicting future cancer burden in the United States by artificial neural networks. Future Oncol. 2021 Jan; 17(2):159-168. PMID: 33305617.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  64. Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells. 2020 12 10; 9(12). PMID: 33321757.
    Citations: 23     Fields:    Translation:HumansCells
  65. Devlies W, Eckstein M, Cimadamore A, Devos G, Moris L, Van den Broeck T, Montironi R, Joniau S, Claessens F, Gevaert T. Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. Cells. 2020 11 17; 9(11). PMID: 33212909.
    Citations: 4     Fields:    Translation:Humans
  66. Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L. Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? Eur Urol. 2021 02; 79(2):232-233. PMID: 33208256.
    Citations: 1     Fields:    Translation:Humans
  67. Montironi R, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M. Exciting experiences in the 'Rocky road to digital diagnostics'. J Clin Pathol. 2021 Jan; 74(1):5-6. PMID: 33132214.
    Citations:    Fields:    Translation:Humans
  68. Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, Scarpelli M, Santoni M, Cimadamore A, Cheng L. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. Eur Urol Focus. 2021 09; 7(5):955-963. PMID: 33132109.
    Citations: 2     Fields:    Translation:Humans
  69. Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. Eur Urol. 2021 01; 79(1):e17-e19. PMID: 33067017.
    Citations:    Fields:    Translation:Humans
  70. Santoni M, Massari F, Aurilio G, Mollica V, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Nolé F, Montironi R. Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy. 2020 12; 12(17):1257-1268. PMID: 32998603.
    Citations: 2     Fields:    Translation:Humans
  71. Rocco B, Sighinolfi MC, Sandri M, Spandri V, Cimadamore A, Volavsek M, Mazzucchelli R, Lopez-Beltran A, Eissa A, Bertoni L, Azzoni P, Reggiani Bonetti L, Maiorana A, Puliatti S, Micali S, Paterlini M, Iseppi A, Rocco F, Pellacani G, Chester J, Bianchi G, Montironi R. Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. Eur Urol Oncol. 2021 10; 4(5):784-791. PMID: 32952095.
    Citations: 9     Fields:    Translation:Humans
  72. Saoud R, Heidar NA, Cimadamore A, Paner GP. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. Cells. 2020 09 17; 9(9). PMID: 32957584.
    Citations: 5     Fields:    Translation:Humans
  73. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. Is There a Role for Immunotherapy in Prostate Cancer? Cells. 2020 09 08; 9(9). PMID: 32911806.
    Citations: 19     Fields:    Translation:Humans
  74. Montironi R, Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Mikuz G. Pathology without microscope: From a projection screen to a virtual slide. Pathol Res Pract. 2020 Nov; 216(11):153196. PMID: 32927307.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  75. Rocco B, Sighinolfi MC, Cimadamore A, Reggiani Bonetti L, Bertoni L, Puliatti S, Eissa A, Spandri V, Azzoni P, Dinneen E, Shaw G, Nathan S, Micali S, Bianchi G, Maiorana A, Pellacani G, Montironi R. Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins. BJU Int. 2020 09; 126(3):336-338. PMID: 32401370.
    Citations: 6     Fields:    Translation:Humans
  76. Cimadamore A, Cheng L, Lopez-Beltran A, Mazzucchelli R, Lucianò R, Scarpelli M, Montorsi F, Montironi R. Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. Eur Urol Oncol. 2021 08; 4(4):558-569. PMID: 32883645.
    Citations: 1     Fields:    Translation:Humans
  77. Montironi R, Cimadamore A. Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading. Virchows Arch. 2021 02; 478(2):375-377. PMID: 32808062.
    Citations: 1     Fields:    Translation:Humans
  78. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763. PMID: 32757789.
    Citations: 4     Fields:    Translation:Humans
  79. Cimadamore A, Montironi R. The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate. Eur Urol Focus. 2021 11; 7(6):1504-1505. PMID: 32811780.
    Citations:    Fields:    Translation:Humans
  80. Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. J Clin Pathol. 2020 Nov; 73(11):695-696. PMID: 32732339.
    Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
  81. Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R. New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? Cells. 2020 06 22; 9(6). PMID: 32580469.
    Citations: 5     Fields:    Translation:Humans
  82. Cantini L, Pecci F, Murrone A, Tomasetti M, Copparoni C, Fiordoliva I, Morgese F, Rinaldi S, Mazzanti P, Rubini C, Cimadamore A, Barbisan F, Giampieri R, Scarpelli M, Santarelli L, Berardi R. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. Lung Cancer. 2020 08; 146:318-326. PMID: 32622302.
    Citations: 2     Fields:    Translation:Humans
  83. Cimadamore A, Aurilio G, Nolé F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells. 2020 06 19; 9(6). PMID: 32575429; PMCID: PMC7348874.
    Citations: 5     Fields:    Translation:HumansCells
  84. Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A, Scarpelli M. Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. Eur Urol. 2020 09; 78(3):478-481. PMID: 32416977; PMCID: PMC7212258.
    Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
  85. Raspollini MR, Montagnani I, Cirri P, Baroni G, Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R, Barnea ER. PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. Int J Biol Markers. 2020 Jun; 35(2):82-90. PMID: 32389051.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  86. Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L. Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells. 2020 04 25; 9(5). PMID: 32344931.
    Citations: 9     Fields:    Translation:Humans
  87. Occhipinti G, Romagnoli E, Santoni M, Cimadamore A, Sorgentoni G, Cecati M, Giulietti M, Battelli N, Maccioni A, Storti N, Cheng L, Principato G, Montironi R, Piva F. Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. Front Genet. 2020; 11:349. PMID: 32351542.
    Citations: 5     
  88. Raspollini MR, Montironi R, Mazzucchelli R, Cimadamore A, Cheng L, Lopez-Beltran A. pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. Virchows Arch. 2020 Jul; 477(1):3-16. PMID: 32296929.
    Citations: 1     Fields:    Translation:HumansAnimals
  89. Montironi R, Cimadamore A, Scarpelli M. From Undergraduate Medical School Student to Visible Pathologist. Arch Pathol Lab Med. 2020 04; 144(4):413-414. PMID: 32233991.
    Citations: 1     Fields:    Translation:Humans
  90. Montironi R, Cimadamore A, Ohashi R, Cheng L, Scarpelli M, Lopez-Beltran A, Moch H. Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. Eur Urol Oncol. 2021 04; 4(2):331-333. PMID: 32199916.
    Citations: 2     Fields:    Translation:Humans
  91. Cimadamore A, Cheng L, Ohashi R, Scarpelli M, Lopez-Beltran A, Moch H, Montironi R. Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. Eur Urol. 2020 07; 78(1):114-116. PMID: 32143925.
    Citations: 1     Fields:    Translation:Humans
  92. Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. Expert Opin Biol Ther. 2020 06; 20(6):539-544. PMID: 32081061.
    Citations: 3     Fields:    Translation:Humans
  93. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Galosi AB, Montorsi F, Montironi R. Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871. Eur Urol. 2020 05; 77(5):e122-e127. PMID: 32089357.
    Citations:    Fields:    Translation:Humans
  94. Rocco B, Sighinolfi MC, Bertoni L, Spandri V, Puliatti S, Eissa A, Reggiani Bonetti L, Azzoni P, Sandri M, De Carne C, Turri F, Cimadamore A, Montironi R, Maiorana A, Micali S, Bianchi G, Pellacani G. Real-time assessment of surgical margins during radical prostatectomy: a novel approach that uses fluorescence confocal microscopy for the evaluation of peri-prostatic soft tissue. BJU Int. 2020 04; 125(4):487-489. PMID: 31971342.
    Citations: 4     Fields:    Translation:Humans
  95. Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, Huang K, Massari F, Lu X, Cimadamore A, Lopez-Beltran A, Cheng L. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol. 2020 04; 31(4):470-479. PMID: 32139297.
    Citations: 35     Fields:    Translation:Humans
  96. Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A. Molecular diagnostics in uro-oncology. Expert Rev Mol Diagn. 2020 02; 20(2):117-121. PMID: 31933387.
    Citations: 2     Fields:    Translation:Humans
  97. Rolim I, Henriques V, Rolim N, Blanca A, Marques RC, Volavšek M, Carvalho I, Montironi R, Cimadamore A, Raspollini MR, Cheng L, Lopez-Beltran A. Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Arch. 2020 Jul; 477(1):111-120. PMID: 31950242.
    Citations: 4     Fields:    Translation:Humans
  98. Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncol. 2020 Feb; 16(5):75-80. PMID: 31916449.
    Citations: 5     Fields:    Translation:HumansCells
  99. Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A. PD-L1 Inhibitors for the Treatment of Prostate Cancer. Curr Drug Targets. 2020; 21(15):1558-1565. PMID: 32516098.
    Citations: 1     Fields:    Translation:HumansAnimals
  100. Cimadamore A, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Moch H. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. Curr Drug Targets. 2020; 21(16):1664-1671. PMID: 32208115.
    Citations: 1     Fields:    Translation:Humans
  101. Mollica V, Santoni M, Di Nunno V, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Montironi R, Massari F. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. Curr Drug Targets. 2020; 21(14):1463-1475. PMID: 32160846.
    Citations:    Fields:    Translation:HumansAnimals
  102. Santoni M, Heng DYC, Aurilio G, Iozzelli A, Servi L, Fabiani A, Giannini M, Mazzucchelli R, Cimadamore A, Scarpelli M, Zaghloul MS, Battelli N, Montironi R. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. Curr Drug Targets. 2020; 21(4):416-423. PMID: 31625471.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  103. Cimadamore A, Montironi R, Serni S, Campi R. Seminal Vesicle Tumor Microenvironment. Adv Exp Med Biol. 2020; 1296:309-318. PMID: 34185301.
    Citations:    Fields:    Translation:HumansAnimals
  104. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers (Basel). 2019 Dec 30; 12(1). PMID: 31905816; PMCID: PMC7016527.
    Citations: 5     
  105. Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Rev Cardiovasc Ther. 2019 Dec; 17(12):917-927. PMID: 31829045.
    Citations: 1     Fields:    Translation:Humans
  106. Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Rev Mol Diagn. 2020 02; 20(2):231-243. PMID: 31795775.
    Citations: 7     Fields:    Translation:HumansCells
  107. Aurilio G, Piva F, Santoni M, Cimadamore A, Sorgentoni G, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R. The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. Int J Mol Sci. 2019 Nov 13; 20(22). PMID: 31766196; PMCID: PMC6888048.
    Citations: 11     Fields:    Translation:HumansAnimals
  108. Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019 Nov; 7(22):690. PMID: 31930091; PMCID: PMC6944605.
    Citations: 26     
  109. Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019 12; 11(17):1507-1521. PMID: 31663411.
    Citations: 3     Fields:    Translation:Humans
  110. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Rev Mol Diagn. 2020 02; 20(2):207-217. PMID: 31640441.
    Citations: 3     Fields:    Translation:HumansCells
  111. Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn. 2020 02; 20(2):255-264. PMID: 31608720.
    Citations: 5     Fields:    Translation:HumansCells
  112. Volavšek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, Cimadamore A, Vau N, Pierconti F, Lopez-Beltran A. Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. Virchows Arch. 2019 Dec; 475(6):735-744. PMID: 31588959.
    Citations: 2     Fields:    Translation:Humans
  113. Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R. Prostate cancer pathology: What has changed in the last 5 years. Urologia. 2020 Feb; 87(1):3-10. PMID: 31545701.
    Citations: 1     Fields:    Translation:Humans
  114. Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Rev Mol Diagn. 2020 02; 20(2):141-150. PMID: 31498685.
    Citations: 6     Fields:    Translation:HumansCells
  115. Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Ann Transl Med. 2019 Sep; 7(Suppl 6):S194. PMID: 31656773; PMCID: PMC6789363.
    Citations: 1     
  116. Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R. Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers (Basel). 2019 Aug 22; 11(9). PMID: 31443386; PMCID: PMC6770077.
    Citations: 7     
  117. Vau N, Henriques V, Cheng L, Blanca A, Fonseca J, Montironi R, Cimadamore A, Lopez-Beltran A. Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. Hum Pathol. 2019 11; 93:6-15. PMID: 31442520.
    Citations:    Fields:    Translation:Humans
  118. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology. Eur Urol. 2020 04; 77(4):e100-e102. PMID: 31420247.
    Citations:    Fields:    Translation:Humans
  119. Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A. Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 2019 Aug; 127(8):545-553. PMID: 31231851.
    Citations: 6     Fields:    Translation:Humans
  120. Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Ann Transl Med. 2019 Jul; 7(Suppl 3):S137. PMID: 31576344; PMCID: PMC6685836.
    Citations: 2     
  121. Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Arch. 2019 Oct; 475(4):445-455. PMID: 31240474.
    Citations: 11     Fields:    Translation:Humans
  122. Gevaert T, Cimadamore A, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncol. 2019 Jul; 15(19):2199-2202. PMID: 31213082.
    Citations: 5     Fields:    Translation:Humans
  123. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers (Basel). 2019 Jun 14; 11(6). PMID: 31207938; PMCID: PMC6627706.
    Citations: 12     
  124. Montironi R, Cheng L, Scarpelli M, Cimadamore A, Montorsi F, Lopez-Beltran A. Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream? Eur Urol. 2019 09; 76(3):e69-e72. PMID: 31176624.
    Citations: 1     Fields:    Translation:Humans
  125. Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clin Drug Investig. 2019 Jun; 39(6):503-519. PMID: 30937824.
    Citations: 10     Fields:    Translation:Humans
  126. Montironi R, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L. Editorial: Emerging Biomarkers in Genitourinary Tumors. Front Oncol. 2019; 9:326. PMID: 31106155; PMCID: PMC6498886.
    Citations: 2     
  127. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Front Oncol. 2019; 9:228. PMID: 31024837; PMCID: PMC6460373.
    Citations: 8     
  128. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G. The Human Microbiota and Prostate Cancer: Friend or Foe? Cancers (Basel). 2019 Mar 31; 11(4). PMID: 30935126; PMCID: PMC6521295.
    Citations: 11     
  129. Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Microbiome and Cancers, With Focus on Genitourinary Tumors. Front Oncol. 2019; 9:178. PMID: 30972292; PMCID: PMC6443990.
    Citations: 6     
  130. Cimadamore A, Palagonia E, Piccinni P, Misericordia M, Galosi AB, Montironi R. Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer. Urologia. 2019 Feb; 86(1):35-38. PMID: 30808261.
    Citations: 2     Fields:    Translation:Humans
  131. Cimadamore A, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers (Basel). 2019 Feb 07; 11(2). PMID: 30736478; PMCID: PMC6407029.
    Citations: 9     
  132. Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 01 11; 8(1). PMID: 30642011; PMCID: PMC6356740.
    Citations: 19     Fields:    Translation:Humans
  133. Bianconi M, Cimadamore A, Faloppi L, Scartozzi M, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Ther Adv Urol. 2019 Jan-Dec; 11:1756287218815372. PMID: 30671136; PMCID: PMC6329040.
    Citations: 2     
  134. Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019 Jan; 74(1):77-96. PMID: 30565299.
    Citations: 30     Fields:    Translation:Humans
  135. Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Curr Drug Metab. 2019; 20(4):305-312. PMID: 30799789.
    Citations: 3     Fields:    Translation:Humans
  136. Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R. New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Front Oncol. 2018; 8:653. PMID: 30622933; PMCID: PMC6308151.
    Citations: 29     
  137. Chovanec M, Albany C, Mego M, Montironi R, Cimadamore A, Cheng L. Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice. Front Oncol. 2018; 8:571. PMID: 30547014; PMCID: PMC6280583.
    Citations: 6     
  138. Cimadamore A, Scarpelli M, Santoni M, Cheng L, Lopez-Beltran A, Montironi R. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. Expert Rev Mol Diagn. 2018 12; 18(12):1021-1028. PMID: 30452305.
    Citations: 2     Fields:    Translation:Humans
  139. Cimadamore A, Scarpelli M, Santoni M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589-97. Eur Urol 2018;74:525-6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? Eur Urol. 2019 04; 75(4):e110-e113. PMID: 30471886.
    Citations: 1     Fields:    Translation:Humans
  140. Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol. 2019 Feb; 72(2):135-139. PMID: 30425122.
    Citations: 11     Fields:    Translation:Humans
  141. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol. 2018; 8:456. PMID: 30450335; PMCID: PMC6225533.
    Citations: 19     
  142. Giunchi F, Cimadamore A, Fiorentino M. Emerging Molecular Technologies in Genitourinary Tumors. Front Oncol. 2018; 8:489. PMID: 30425967; PMCID: PMC6218401.
    Citations: 1     
  143. Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Front Oncol. 2018; 8:397. PMID: 30319966; PMCID: PMC6165898.
    Citations: 12     
  144. Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, Fiorentino M, Ciccarese C, Iacovelli R, Cheng L, Lopez-Beltran A, Massari F, Montironi R. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncol. 2018 Oct; 14(25):2559-2564. PMID: 30141348.
    Citations: 3     Fields:    Translation:Humans
  145. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists. Eur Urol. 2018 12; 74(6):e141-e144. PMID: 30093173.
    Citations: 1     Fields:    Translation:Humans
  146. Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A. Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? Eur Urol. 2019 01; 75(1):32-34. PMID: 30093172.
    Citations:    Fields:    Translation:Humans
  147. Di Nunno V, Santoni M, Cimadamore A, Battelli N, Massari F. Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? Eur Urol. 2018 11; 74(5):e118-e119. PMID: 30017397.
    Citations: 1     Fields:    Translation:Humans
  148. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev Mol Diagn. 2018 07; 18(7):645-655. PMID: 29912582.
    Citations: 13     Fields:    Translation:Humans
  149. Montironi R, Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. Int J Biol Markers. 2018 Nov; 33(4):331-334. PMID: 29945478.
    Citations: 3     Fields:    Translation:Humans
  150. Giulietti M, Santoni M, Cimadamore A, Carrozza F, Piva F, Cheng L, Lopez-Beltran A, Scarpelli M, Battelli N, Montironi R. Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Front Oncol. 2018; 8:221. PMID: 29951374; PMCID: PMC6008382.
    Citations: 8     
  151. Santoni M, Piva F, Conti A, Santoni A, Cimadamore A, Scarpelli M, Battelli N, Montironi R. Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. Eur Urol. 2018 10; 74(4):521-522. PMID: 29891391.
    Citations: 12     Fields:    Translation:Humans
  152. Massari F, Santoni M, di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, Battelli N, Montironi R. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treat Rev. 2018 Jul; 68:80-85. PMID: 29886353.
    Citations: 11     Fields:    Translation:Humans
  153. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018; 7:212528. PMID: 29899754; PMCID: PMC5992965.
    Citations: 30     
  154. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun; 19(9):1021-1025. PMID: 29851529.
    Citations: 5     Fields:    Translation:Humans
  155. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R. Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. Minerva Urol Nefrol. 2019 04; 71(2):189-190. PMID: 29761691.
    Citations:    Fields:    Translation:Humans
  156. Montironi R, Cimadamore A, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):685-693. PMID: 29699428.
    Citations: 3     Fields:    Translation:Humans
  157. Meletani T, Cantini L, Lanese A, Nicolini D, Cimadamore A, Agostini A, Ricci G, Antognoli S, Mandolesi A, Guido M, Alaggio R, Giuseppetti GM, Scarpelli M, Vivarelli M, Berardi R. Are liver nested stromal epithelial tumors always low aggressive? World J Gastroenterol. 2017 Dec 14; 23(46):8248-8255. PMID: 29290661; PMCID: PMC5739931.
    Citations: 2     Fields:    Translation:Humans
  158. Cimadamore A, Gasparrini S, Mazzucchelli R, Doria A, Cheng L, Lopez-Beltran A, Santoni M, Scarpelli M, Montironi R. Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. Front Oncol. 2017; 7:305. PMID: 29312884; PMCID: PMC5732923.
    Citations: 10     
  159. Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M. Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. Arch Pathol Lab Med. 2017 11; 141(11):1460-1461. PMID: 29072947.
    Citations: 4     Fields:    Translation:Humans
  160. Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian J Androl. 2017 Aug 04. PMID: 28782737; PMCID: PMC6337944.
    Citations: 1     Fields:    
  161. Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Rev Mol Diagn. 2017 08; 17(8):781-789. PMID: 28598696.
    Citations: 3     Fields:    Translation:Humans
  162. Cimadamore A, Scarpelli M, Piva F, Massari F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A, Montironi R. Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncol. 2017 May; 13(12):1105-1114. PMID: 28147707.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  163. Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montironi R. Epigenetic Modifications and Modulators in Prostate Cancer. Crit Rev Oncog. 2017; 22(5-6):439-450. PMID: 29604923.
    Citations: 6     Fields:    Translation:HumansCells
  164. Guerra E, Cimadamore A, Simeone P, Vacca G, Lattanzio R, Botti G, Gatta V, D'Aurora M, Simionati B, Piantelli M, Alberti S. p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer. 2016 08 18; 16:649. PMID: 27538498.
    Citations: 10     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cimadamore's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (245)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.